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Abstract—A new, simple, selective, sensitive, fast, economical, 
and reliable fluorescence quenching method for the quantitation of 
valsartan was investigated using basic fuchsin act as a fluorometric 
dye. The method was depended on the detection quenching influence 
of valsartan on the fluorescence intensity of basic fuchsin and 
the reaction between valsartan and basic fuchsin in a McIlvaine 
buffer medium at pH = 6 to yield a new basic fuchsin–valsartan 
non-fluorescent complex. The excitation and emission of basic 
fuchsin fluorescence signal were identified at 535 and 728 nm, 
respectively. A fluorescence quenching value (ΔF) displayed a very 
good linear relationship (R2 = 0.9992) with valsartan concentration 
ranging from 0.003 to 3 μg/mL, a detection limit as low as 
0.0009 μg/mL with a high precision and accuracy (RSD% <3). 
Significantly, no interference effect was found due to the presence 
of other ingredients commonly found in medical formulations. 
The acquired data were statistically compared with those acquired 
from reported chromatographic method and were observed to 
be in excellent agreement at a 95% confidence level; the planned 
fluorescence quenching procedure was subsequently utilized to 
detected the concentration of valsartan in spiked biological fluids 
and commercial medical tablets.
Index Terms—Basic fuchsin, Fluorescence quenching, 
Pharmaceutical analysis, Valsartan.
I. Introduction
In recent years, cardiovascular diseases have begun to be 
recognized as the principal causes of death in the majority of 
countries worldwide (Kaabipour, et al., 2020). Cardiovascular 
diseases are associated with heart failure, ischemic heart 
disease, rheumatic heart disease, cerebrovascular disease, 
coronary heart disease, high cholesterol levels, and high 
blood pressure (Kumar, et al., 2015). High blood pressure is 
classified as a principal reason for an array of cardiovascular 
diseases. The control and treatment of higher blood 
pressure are significant in the avoidance of the effects of 
cardiovascular diseases (Shah, et al., 2017).
Valsartan is taken by mouth as well as highly active is a 
non-peptide angiotensin II receptor antagonist and potentials 
through preventing the actions of angiotensin II, beside a 
high ability to suppress the type I angiotensin receptor (Azadi 
and Ahmadi, 2019), so is utilized as an antihypertensive drug 
(Gadepalli, et al., 2014; Shah, et al., 2017). Chemically, 
Valsartan is labeled as“N-(1-oxopentyl)-N-[[2ʹ-(1H-tetrazol-
5-yl)[1,1ʹ-biphenyl]-4-yl]methyl]-L-aline”(C24H29N5O3) 
(Gadepalli, et al., 2014; Qader, Salih and Tahir, 2018), as 
shown in Fig.1.
In a review of associated scientific articles, numerous 
previous analytical methods have been developed and used for 
the quantitation of valsartan in samples containing biological 
fluids and pharmaceutical products. Published methods involve 
the separation and determination of valsartan by various 
analytical approaches either with or without other drugs such 
as high-performance liquid chromatography (HPLC) through 
different detectors such as UV detectors (Kumar, et al., 2015; 
Pebdani, et al., 2016; Babarahimi, et al., 2018; Shaikh, et al., 
2020; Marghany, et al., 2020), fluorescence detection (Macek, 
Klima and Ptacek, 2006; del Rosario Brunetto, et al., 2009), 
as well as diode-array detection (Farajzadeh, Khorram and 
Pazhohan, 2016); a modern class of separation system based 
on “ultra-high-performance liquid chromatography” (UPLC) 
(Krishnaiah, et al., 2010; Vojta, et al., 2015; Moussa, et al., 
2018); liquid chromatography–tandem mass spectrometry (LC–
MS/MS) (Selvan, et al., 2007, Koseki, et al., 2007 , Annadi, 
El Sheikh and Mohamed, 2019); electroanalytical voltammetry 
methods (Eisele, et al., 2014; Mansano, et al., 2015); and UV-
vis spectrophotometry (Satana, et al., 2001; Erk, 2002; Lotfy, 
et al., 2015; Eissa and Abou Al Alamein 2018; Meselhy, et 
al., 2020; Kamal, Marie and Hammad 2020). As well the 
fluorescence determination of valsartan, several procedures have 
been described in previous articles for its determination were 
including native fluorescence, a first derivative fluorescence and 
the synchronous fluorescence (Cagigal, et al., 2001; Shaalan 
and Belal, 2010; El-Shaboury, et al., 2012; El-Kosasy, et al., 
2015; Dinc, Ertekin and Buker, 2017; Ragab, et al., 2017).
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Basic fuchsin dye is recognized as a member of 
triphenylmethane group, with a chemical formula of 
C20H20ClN3; it is also known as Magenta II because it is also 
known as Magenta II because it is a mix of pararosaniline, 
rosaniline, as well as Magenta II dyes. Fuchsin itself is 
inflammable, as well as having various properties such 
as being bactericidal, fungicidal and an anesthetic. It is 
commonly employed as coloring reagent for different 
industrial products such as textile, leather, fibers, paper, 
and cotton; it can also be used to stain collagen, muscle, 
mitochondria, and the tubercle bacillus (Pathrose, et al., 
2014; Pathrose, et al., 2014; Pathrose, et al., 2016; Graham, 
et al. 2017; Ning, et al., 2018). 
To the best of our knowledge, basic fuchsin has not 
been applied before for the analysis of drugs. In the current 
paper, a new quenching spectrofluorimetric procedure has 
been developed for the quantitative analysis of valsartan 
employing basic fuchsin as a fluorescence reagent. The 
developed method is simple, inexpensive, accurate, selective, 
and highly sensitive. It was applied for the determination 
of valsartan in pharmaceutical tablets and spiked biological 
fluids. Furthermore, the experimental conditions for an 
advanced spectrofluorimetric method were optimized.
II. Experimental
A. Apparatus
The fluorescence spectra and measurements were carried 
out using a Cary Eclipse fluorescence spectrophotometer 
(Agilent Technologies, USA) equipped with a xenon flash 
lamp, where the slit width was fixed at 5 nm. All fluorescence 
measurements were achieved in 1 cm quartz cell. The pH of 
the buffer systems was determined through an S-25 pH meter 
(Wincom Company Ltd., China).
B. Chemicals and Reagents
Valsartan standards were provided from Awamedica Drugs 
Company, Erbil-K. R. of Iraq, where a standard solution 
of 1 mg/mL was prepared by dissolving 50 mg of standard 
valsartan powder in 50 mL ethanol (Merck, Germany) 
with carefully mixing, and was subsequently stored in 
a refrigerator. Every day, working standard solutions of 
valsartan were prepared using the appropriate dilution of the 
standard solution with ethanol.
Basic fuchsin was purchased from Sigma-Aldrich, USA. 
Solutions of basic fuchsin were prepared at a concentration 
of 5 × 10−4 mol/L by dissolving 8.4 mg of basic fuchsin in 
50 mL ethanol (Merck, Germany).
According to a previous procedure reported 
(El-Kosasy, et al., 2015), diverse buffer systems with pH 
values ranging from 1 to 11 were prepared, respectively. 
For pH 1, the standard Citrate buffer solution was created 
through 0.1 mole/L sodium citrate (Sigma-Aldrich, USA), 
then regulated for desired pH using 0.1 mole/L hydrochloric 
acid (Sigma‐Aldrich, USA). For a pH scale between 2 and 8, 
the standard McIlvaine buffer solutions were preparation by 
mixing numerous volumes from 0.2 mol/L disodium hydrogen 
phosphate solution (Merck, Germany) as well as 0.1 mol/L 
citric acid solution (Merck, Germany). For a pH scale between 
11 to 9, borate buffer solutions were created, by mixing several 
volumes from 0.1 mol/L sodium hydroxide solution (Sigma‐
Aldrich, USA) with several volumes of 0.05 mol/L sodium 
tetraborate solution (Sigma-Aldrich, USA).
All reagents and solvents were of extra pure grade. 
Valsartan tablets, Diovan® (Novartis International AG. 
Switzerland), Valsartan Awa® (Awamedica Drugs Company, 
Erbil-K. R. of Iraq), and Arbiten® (JOSWE medical. Jordan) 
containing 160 mg of active ingredient were purchased from 
a local pharmacy.
C. Sample Preparation
Ten tablets from three different brands of pharmaceutical 
products were carefully weighed, ground, and mixed to 
produce appropriate powders, after which exact weights of 
powders were placed in 50 mL volumetric flasks and dissolved 
using 40 mL of ethanol and sonication for 15 min. The 
solutions so obtained were filtrated by Whatman® quantitative 
filter paper, ashless, Grade 41 (Merck, Darmstadt, Germany), 
before washing and diluting to 50 mL using ethanol.
D. Procedure for Spiked Urine and Serum Samples (Gong 
and Zhu, 2013)
Initially, the drug-free serum and urine samples were 
obtained from Rizgary Hospital (Erbil-K. R. of Iraq) and 
kept at −20°C until analysis and thawed to lab temperature 
before use. The serum and urine samples were individually 
diluted by 1000- and 500-fold using deionized water. A 
1 mL serum or urine sample was spiked with an appropriate 
concentration of valsartan standard solution, giving final 
valsartan concentrations of 0.5, 1, and 3 μg/mL.
E. Recommended Procedure
To detect a content of valsartan, 1.5 mL basic 
fuchsin (5 × 10−4 mol/L), 2 mL McIlvaine buffer solution 
(pH 6), and Aliquot volumes of the working standard or 
sample solutions over concentration range 0.003–3 μg/mL of 
Fig. 1. Chemical structure of valsartan.
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valsartan were diluted to 10 mL, then mixed thoroughly for 
15 min at lab temperature. The fluorescence intensity of basic 
fuchsin was recorded versus a blank solution at an excitation 
wavelength of 535 nm as well as emission at 728 nm. 
III. Results and Discussion
A. Quenching Excitation and Emission Spectra of Basic 
Fuchsin with Valsartan
Basic fuchsin has high native fluorometric signal with 
excitation/emission wavelengths of 535/728 nm (Fig. 2a), 
whereas valsartan does not appear to have any fluorescence 
emission properties. Furthermore, under experimental 
conditions the fluorescence spectra of basic fuchsin were 
acquired from reaction with a 1 μg/mL concentration of 
valsartan (Fig. 2b). From Fig. 2, it can be observed that the 
fluorescence signal of basic fuchsin was quenched rapidly 
when a drug was added though no change to both the position 
and shape of the emission peak. The acquired data showed that 
there was an interaction between valsartan and basic fuchsin. 
Hence, basic fuchsin could be used as a quenching fluorescent 
reagent for spectrofluorimetric determination of valsartan.
B. Influence of the Type and Volume Buffer Systems
The influence of the buffer solutions from pH = 1 to 11 
on fluorescence quenching (ΔF) was assessed. For pH1 was 
utilized citrate buffer solution, whereas for the pH range 
2–8 was used McIlvaine buffer solutions, finally for the pH 
range 9–11 was used borate buffer solutions. The acquired 
data exhibited that the ΔF reached a maximum value when 
the McIlvaine buffer (pH 6) solution was used (Fig. 3a). 
The McIlvaine buffer and pH 6 were selected as optimum 
values for further studies. From Fig. 3b, it can be seen that 
ΔF reached a maximum when the volume of buffer solution 
was 2 mL; accordingly, a 2 mL volume of McIlvaine buffer 
medium was nominated as the best volume for the optimized 
fluorescence method.
C. Influence of Basic Fuchsin Concentration
The influence of different concentrations of basic fuchsin 
reagent (1, 2, 3, 4, 5, and 6 × 10−5 mol/L) on fluorescence 
quenching (ΔF) signal was determined. The fluorescence 
quenching was maximum signal after the molar concentration 
of basic fuchsin = 5 × 10−5 mol/L (Fig. 4); hence, this molar 
concentration was selected for following optimization tests. 
D. Influence of the Time Reaction
The optimized reaction time was investigated by following 
the fluorescence intensity at 728 nm at lab temperature. From 
Fig. 5, it was determined that the complex formed and was 
stabilized after 5 min of mixing, and the associated fluorescence 
quenching, ΔF, remained stable for at least 150 min.
E. Fluorescence Quenching Spectrum and the Standard 
Calibration Curve for Determination of Valsartan
Under optimum experimental conditions, the 
fluorescence quenching value, ΔF, of the basic fuchsin 
Fig. 2. Fluorescence excitation as well emission spectra of (a) Basic 
fuchsin (5 × 10−5 mol/L). (b) Basic fuchsin (5 × 10−5 mol/L) in the 
presence of valsartan (1 μg/mL), McIlvaine buffer solution (pH 6).
Fig. 3. Influences of (a) various buffer systems on fluorescence 
quenching (ΔF). (b) McIlvaine buffer volume on fluorescence quenching 
(ΔF) of the Basic fuchsin (5 × 10−5 mol/L) in the presence of valsartan 
(1 μg/mL).
reactions with different concentrations of valsartan 
(0.003–3 μg/mL) were determined. From Fig. 6a, it 
can be observed that fluorescence quenching decreased 
progressively with increase of valsartan concentrations in 
the solution, in a manner proportional to the concentration 
of the valsartan. Thus, basic fuchsin can be used to 
determine the concentration of valsartan.
Under optimum fluorescence experimental conditions, 
a standard calibration curve was created using various 
external standard concentrations (Fig. 6b). The correlation 
coefficient was 0.9992, demonstrating excellent linearity 
a
b
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indicate no significant interference from that pharmaceutical 
tablet excipients and that the proposed procedure is highly 
selective.
G. Precision and Accuracy of the Proposed Procedure
Six measurements at three different concentrations of valsartan 
representing low, medium, and high concentrations from a range 
of the linearity were taken. The low value of the relative standard 
deviation percentage (RSD % < 3) points to high precision of the 
recommended procedure for quantitative measurements of the 
fluorescence quenching intensity of valsartan. Likewise, the very 
good percentage of recoveries of standard valsartan indicates the 
high accuracy of the method (Table II).
Fig. 4. Influence of various molar concentrations of basic fuchsin (1, 
2, 3, 4, 5, and 6 × 10−5 mol/L) on fluorescence quenching (ΔF) in the 
presence of valsartan (1 μg/mL), McIlvaine buffer solution (pH 6).
Fig. 5. Influence of the time reaction on fluorescence quenching (ΔF) of 
basic fuchsin (5 × 10−5 mol/L) in the presence of valsartan (1 μg/mL), 
McIlvaine buffer solution (pH 6).
over a concentration range of 0.003–3 μg/mL, as achieved 
through the equation ΔF = 104.6 CVAL (μg/mL) + 100.63. 
According to the “International Union of Pure and Applied 
Chemistry (IUPAC) principles,” a detection limit (DL) 
term correspond with a formula (3.3 × SDblank /F) and 
quantification limit (QL) term correspond with a formula 
(10 × SDblank/F), respectively, wherein SDblank represents a 
standard deviation of six blank determinations, whereas 
F represents a slope of the constructed calibration graph. 
From optimum quenching method, the DL value of 
valsartan was 0.0009, whereas the QL value of valsartan 
was 0.0028 μg/mL.
F. Selectivity of the Proposed Procedure
The selectivity of the planned fluorescence procedure 
was assessed through determining the standard solution 
of valsartan (1 μg/mL) in the presence of pharmaceutical 
tablet materials such as citric acid, glucose, sucrose, lactose, 
silica, and other coexisting ionic species, the results of which 
are displayed in Table I. It was established that the limit 
of the concentrations of pharmaceutical tablet excipients 
that could be tolerated should produce an error of < ± 4% 
in the analysis of the valsartan. Furthermore, these results 
TABLE I
Selectivity in the analysis of valsartan by basic fuchsin
Tablet excipients species Tolerance conc. (µg/mL) Error a%












aAverage of five analyses
Fig. 6. (a) Influence of diverse standard concentrations of valsartan 
(0.003, 0.01, 0.05, 0.1, 0.5, 1.2, and 3 μg/mL) on a quenching signal (ΔF) 
of basic fuchsin (5 × 10−5 mol/L), McIlvaine buffer solution (pH 6). (b) 
Standard calibration graph for the spectrofluorometric determination of 
valsartan using basic fuchsin.
a
b
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H. Stoichiometry of the Spectrofluorimetric Reaction
The molar ratio procedure was applied to conclude 
the composition ratio of the fluorescence reaction 
TABLE II







0.5 0.48 94.00 2.58
1.0 1.06 106.0 1.94
3.0 3.08 102.6 1.57
aAverage of six determinations
Fig. 7. Molar ratio plot for the stoichiometry of reaction quenching 
between basic fuchsin and valsartan.
Scheme 1: Schematic illustration of fluorescence quenching of basic fuchsin by valsartan through construction of a basic fuchsin–valsartan complex.
between valsartan and basic fuchsin was represented as a 
fluorometric dye. Fig. 7 shows a plot of molar ratio [BF]/
[VAL] against ΔF. From this, it was established that the 
stoichiometry ratio of the valsartan:basic fuchsin complex 
was 1:1. Correspondingly, the planned mechanism for 
fluorescence quenching reaction through a construction 
of a basic fuchsin–valsartan complex was illustrated by 
Scheme 1.
I. The type of Fluorescence Quenching and Effect of 
Temperature 
Often, fluorescence quenching types generally contain 
dynamic and static modes of quenching. The actual form 
of quenching process can be described by the Stern–Volmer 
equation (Lakowicz, 2013):
F0/F = 1 + Rsv [VAL]
F0 and F are characterized as the intensities of fluorescence 
of basic fuchsin dye with and without valsartan, respectively; 
Rsv refers to the Stern–Volmer quenching constant; whereas 
VAL indicate to a valsartan concentration act as the quencher.
The results obtained from the curve of the Stern–Volmer 
equation in linear form indicates the type of quenching that 
occurs in single static or dynamic mode, whereas a more 
curved form indicates a type of quenching that incorporates 
both static and dynamic modes.
However, the type of quenching cannot be discriminated 
from a plot of the Stern–Volmer equation, so one of the 
significant approaches to identifying static and dynamic 
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TABLE III
Quantitative measurements of valsartan in commercial pharmaceutical tablets THROUGH the proposed fluorescence quenching and a reported 
HPLC method
Valsartan Brands (160 mg/tablet) Results from Proposed method Results from HPLC methodc Recovery % Error %a t and F valuesb
Diovan 162.23 159.36 101.80 1.80 t = 1.15, F = 1.02
Valsartan Awa 164.57 161.11 102.14 2.14 t = 1.76, F = 1.18
Arbiten 161.49 160.27 100.76 0.76 t = 0.94, F = 1.07
aResults average were obtained by five determinations.  bStatistical analysis (t = 2.78, F = 6.39, confidence level = 95% and n = 5).  cHPLC (Tatar and Saglik 2002)
fuchsin in the presence of valsartan as a quenching reagent 
(Fig. 8b).
For the dynamic mode, there were no observed changes to 
the UV spectra of basic fuchsin dye with or without valsartan 
at pH 6 (Gong and Zhu, 2013).
The investigation proved that there was practically no 
change between the absorption spectra of basic fuchsin 
fluorescence dye alone and that of basic fuchsin in combination 
with valsartan. From this study, it can be construed that the 
fluorescence quenching of basic fuchsin fluorescence dye 
introduced using valsartan is dynamic in nature.
J. Application of the Fluorescence Quenching Method
A fluorescence quenching method through basic fuchsin 
as a fluorometric dye was effectively utilized to determine 
valsartan concentrations in various pharmaceutical products. 
To validate the suggested procedure, a data listed in 
Table III were compared with those gained by a reference 
HPLC method (Tatar and Saglik, 2002), and the comparison 
data were analyzed using statically theoretical factors (t test 
and F test), where these data indicate good agreement with 
the reference method.
The proposed quenching procedure was also applied to 
the detection of valsartan concentrations in spiked serum 
and urine samples (Table IV) with a very good recovery 
percentage range (97−108%).
Table V compares valsartan drug concentrations 
determined in various samples in this proposed approach with 
those reported from the previous approaches. Compared with 
classical analytical approaches, the method advocated here is 
simple, takes very little time, and is of very low cost for an 
analytical system, and which returns very good precision and 
accuracy.
TABLE IV
Quantitative measurements of valsartan in spiked serum and urine 
samples using the proposed fluorescence quenching method







































aND: No determined.  bThe average value from five measurements
modes comes from the study of the effect of temperature 
and the assessment of quenching constant values (Rsv). For 
the dynamic mode, the values of Rsv are improved with 
an enhanced quenching reaction temperature, whereas 
for the static mode the opposite influence was detected 
(Lakowicz, 2013).
The Rsv constants at three temperatures (298, 300, and 
305 K) are presented in Fig. 8a. The linear function of 
F0/F against [VAL] showed whether a quenching mode was 
dynamic or static through a single process. Fig. 8a shows 
that the values of Rsv were increased with increasing reaction 
temperature, demonstrating the probable fluorescence 
mechanism of basic fuchsin through valsartan was taking 
place via a dynamic quenching process.
The validation of a dynamic quenching process was 
establishing by the ultraviolet (UV) spectra of basic 
Fig. 8. (a) Stern–Volmer graphs for quenching process at various 
temperatures (298, 300, and 305 K), basic fuchsin (5 × 10−5 mol/L), 
McIlvaine buffer solution (pH 6). (b) Influence of valsartan (1 μg/mL) 
on UV absorption spectra of basic fuchsin (5 × 10−5 mol/L), McIlvaine 
buffer solution (pH 6).
a
b
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TABLE V
Comparison of the proposed method with other previous analytical methods for valsartan determination
Analytical Method DL (µg/mL) QL (µg/mL) REF.
HPLCa 1.0 - (Carlucci, Carlo and Mazzeo, 2000)
HPLC 0.0148 0.0449 (Kumar, et al. 2015)
LC–MS/MSb 0.005 - (Shah, et al. 2017)
LC–ESIMS/ MSc 0.0005 0.001 (Gadepalli, et al. 2014) 
HPLC - 0.098 (Macek, Klima, and Ptacek 2006)
HPLC 0.001 0.003 (del Rosario Brunetto, et al. 2009)
SB-DLLME–HPLC–DADd 0.0003 0.001 (Farajzadeh, Khorram, and Pazhohan, 2016)
HPLC–UV 0.15 0.50 (Ibrahim, et al., 2018)
HPLC–UV 8.01 24.2 (Shaikh, et al., 2020)
HPLC–UV 0.053 0.16 (Marghany, et al., 2020)
UV Spectrophotometry 0.51 1.70 (Satana, et al., 2001)
Ratio derivative spectrophotometry 0.628 2.09 (Dinc, Uslu, and Özkan 2004)
Spectrofluorimetric 0.40 0.50 (Cagigal, et al., 2001)
Spectrofluorimetric 0.001 0.004 (Shaalan and Belal, 2010)
Spectrofluorimetric 0.002 0.005 (El-Shaboury, et al., 2012)
Spectrofluorimetric 0.004 0.013 (El-Kosasy, et al., 2015)
First derivative fluorimetry (D1) 0.0435 0.1318 (Ragab, et al., 2017)
Direct Spectrofluorimetric 0.0442 0.1339 (Ragab, et al., 2017)
First Derivative Synchronous Spectrofluorimetric 0.027 0.083 (Shalan, El-Enany and Belal, 2015)
Voltammetry 0.0033 0.01002 (Ragab, et al., 2019)
Fluorescence Quenching 0.0009 0.0028 This work
aHPLC: High-performance liquid chromatography. bLC–MS/MS: Liquid chromatography–tandem mass spectrometry. cLC–ESIMS/MS: Liquid chromatography–electro spray 
ionization/tandem mass spectrometry. dSB-DLLME–HPLC–DAD: Solid based-disperser liquid–liquid micro-extraction–high-performance liquid chromatography–diode array detector
IV. Conclusion
In this research, a newly advanced fluorescence quenching 
procedure using basic fuchsin as a fluorescence dye was 
devised and confirmed for the determination of valsartan. 
The interaction of the valsartan with basic fuchsin resulted 
in the production of an ion-associated complex related 
to the quenching of basic fuchsin fluorescence dye using 
a dynamic quenching mode. By the utilize of optimized 
model for studding the essential empirical variables, to 
acquire experimental results and assessment valsartan 
recovery value. Furthermore, the significant benefits of 
the new quenching method are that it is sensitive, simple, 
cheap, and fast, permitting the effective determination 
of valsartan at a parts-per-million concentration with 
a DL of 0.0009 and QL 0.0028 (μg/mL). An advanced 
procedure was employed for the quantitative measurement 
of valsartan in various brands of medical tablets, with a 
very good recovery percentage of between of 100.76 and 
102.14, without any significant interference from common 
tablet excipients. Further, this fluorescence quenching 
method was applied to determine the concentration of 
valsartan in spiked human serum and urine samples. 
Hence, the results suggest that basic fuchsin could act as 
an efficiently type of a fluorometric dye for applications in 
clinical and pharmacological fields.
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